Brief: Inhibikase Therapeutics Announces Dosing Of First Subjects In Its '501' Bioequivalence Study Of Ikt-001Pro
12/12/2022 21:22
Dec 12 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS ANNOUNCES DOSING OF FIRST SUBJECTS
IN
ITS '501' BIOEQUIVALENCE STUDY OF IKT-001PRO
Source text for Eikon: ID:nPncfJB0Ka
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share